Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine

Cancer Immunology, Immunotherapy

Volumn 63, Issue 8, 2014, Pages 779-786

  Hu, Yinin ^a   Petroni, Gina R ^a   Olson, Walter C ^a   Czarkowski, Andrea ^b   Smolkin, Mark E ^a   Grosh, William W ^a   Chianese Bullock, Kimberly A ^a   Slingluff, Craig L ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

CD4 T cells; Immunogenicity; Melanoma; Peptide vaccines

Indexed keywords

CANCER TESTIS ANTIGEN; COMBINATION MELANOMA HELPER PEPTIDE VACCINE; EPITOPE; FREUND ADJUVANT; GAMMA INTERFERON; GLYCOPROTEIN GP 100; MELAN A; MONOPHENOL MONOOXYGENASE; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNIZATION; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; HLA SYSTEM; HUMAN; IMMUNOGENICITY; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ALLELES; AMINO ACID SEQUENCE; ANTIGENS, CD4; CANCER VACCINES; CELL DIFFERENTIATION; EPITOPES; HLA ANTIGENS; HUMANS; MELANOMA; MOLECULAR SEQUENCE DATA; PEPTIDES;

EID: 84906790025     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1551-x     Document Type: Article

References (40)

1. Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A et al (2002) Characterization of CD4(+) CTLs ex vivo. J Immunol 168:5954-5958
2. Greenberg PD, Kern DE, Cheever MA (1985) Therapy of disseminated murine leukemia with cyclophosphamide and immune lyt-1+, 2-T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med 161:1122-1134 (Pubitemid 15011329)
3. Hunder N, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R et al (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698-2703 (Pubitemid 351860862)
4. Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE et al (2004) Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother 27:472-477 (Pubitemid 39447355)
5. Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P et al (2003) Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 26:349-356 (Pubitemid 36858719)
6. Wong R, Lau R, Chang J, Kuus-Reichel T, Brichard V, Bruck C et al (2004) Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Clin Cancer Res 10:5004-5013 (Pubitemid 39099774)
7. Slingluff CL Jr, Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M et al (2008) Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 26:4973-4980
8. Slingluff CL Jr, Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH et al (2013) A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res 19:4228-4238
9. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A (1989) Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 19:2237-2242 (Pubitemid 20024747)
10. Slingluff CL Jr, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH et al (2001) Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 7:3012-3024 (Pubitemid 32963818)
11. Johnson RP, Trocha A, Yang L, Mazzara GP, Panicali DL, Buchanan TM et al (1991) HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J Immunol 147:1512-1521
12. Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL Jr et al (2000) Melan-A/MART -1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci USA 97:400-405 (Pubitemid 30055843)
13. Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A et al (1996) Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 183:1965-1971 (Pubitemid 26158888)
14. Kobayashi H, Kokubo T, Sato K, Kimura S, Asano K, Takahashi H et al (1998) CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res 58:296-301 (Pubitemid 28047070)
15. Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C et al (1999) Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 189:871-876 (Pubitemid 29189692)
16. Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R et al (1999) Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 189:767-778
17. Halder T, Pawelec G, Kirkin AF, Zeuthen J, Meyer HE, Kun L et al (1997) Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res 57:3238-3244 (Pubitemid 27351741)
18. Li K, Adibzadeh M, Halder T, Kalbacher H, Heinzel S, Muller C et al (1998) Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and annexin II eluted from melanoma cells. Cancer Immunol Immunother 47:32-38 (Pubitemid 28430528)
19. Consogno G, Manici S, Facchinetti V, Bachi A, Hammer J, Conti-Fine BM et al (2003) Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood 101:1038-1044 (Pubitemid 36139377)
20. Benteyn D, Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B et al (2013) Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int 2013:976383
21. Wilgenhof S, Van Nuffel AM, Benteyn D, Corthals J, Aerts C, Heirman C et al (2013) A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 24:2686-2693
22. Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB et al (2009) Effect of granulocyte/macrophage col-ony- stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 15:7036-7044
23. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF et al (2013) Persistent antigen at vaccination sites induces tumorspecific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med 19:465-472
24. Salerno EP, Shea SM, Olson WC, Petroni GR, Smolkin ME, McSkimming C et al (2013) Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete freund's adjuvant, with or without peptide. Cancer Immunol Immunother 62:1149-1159
25. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH (2007) CD8+ CTL priming by exact peptide epitopes in incomplete freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 179:5033-5040
26. Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C et al (1999) Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol 163:2928-2936 (Pubitemid 29399225)
27. Kittlesen DJ, Thompson LW, Gulden PH, Skipper JC, Colella TA, Shabanowitz J et al (1998) Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. J Immunol 160:2099-2106 (Pubitemid 28119887)
28. Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X et al (1998) Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol 161:6985-6992 (Pubitemid 28562247)
29. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A et al (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176:1453-1457
30. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E et al (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921-930 (Pubitemid 24065650)
31. Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW et al (1994) Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91:2105-2109 (Pubitemid 24092051)
32. Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y et al (1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183:527-534 (Pubitemid 26059516)
33. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S et al (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968
34. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J et al (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-719 (Pubitemid 24185883)
35. Huang LQ, Brasseur F, Serrano A, De Plaen E, van der Bruggen P, Boon T et al (1999) Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J Immunol 162:6849-6854 (Pubitemid 29309414)
36. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR et al (1994) Identification of the immunodominant peptides of the MART -1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180:347-352 (Pubitemid 24181083)
37. Romero P, Dutoit V, Rubio-Godoy V, Lienard D, Speiser D, Guillaume P et al (2001) CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. Clin Cancer Res 7:766s-772s (Pubitemid 33600925)
38. Skipper JC, Kittlesen DJ, Hendrickson RC, Deacon DD, Harthun NL, Wagner SN et al (1996) Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from pmel-17/gp100. J Immunol 157:5027-5033 (Pubitemid 126449583)
39. Hogan KT, Sutton JN, Chu KU, Busby JA, Shabanowitz J, Hunt DF et al (2005) Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members. Cancer Immunol Immunother 54:359-371 (Pubitemid 40238930)
40. Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA (1998) A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol 161:3598-3606